Pneumonia News

The Healio editors have compiled a list of the most-read pulmonology news published in September.

The FDA has approved Fetroja for patients aged 18 years or older with hospital-acquired and ventilator-associated bacterial pneumonia, Shionogi announced.

Oral dexamethasone reduced length of stay and ICU admissions in adults with community-acquired pneumonia, according to research presented at the virtual European Respiratory Society International Congress.

Physical and occupational therapy visits were inversely associated with the risk for hospital readmission and death in patients with pneumonia, according to a study published in JAMA Network Open.

Pulmonary vascular dilation appears to play a role in hypoxemia in patients with COVID-19-related pneumonia, researchers reported in a new study published in the American Journal of Respiratory and Critical Care Medicine.

Artificial intelligence can help predict the chance of resistant organisms appearing in sputum cultures in the ER, helping to guide therapy, according to findings presented during the ASM Microbe virtual meeting.

Some active ingredients in mouthwash are effective against pneumonia-causing bacteria, according to the results of an in vitro study presented during ASM Microbe, which is being held virtually.

Nearly 20% of patients treated for pneumonia did not display pneumonia symptoms on their first day of treatment, but antibiotics were used for 3 days or more after symptoms ceased in one-third of patients, according to a large cohort study.

Adults with any degree of obesity are more than twice as likely to experience respiratory failure and four times as likely to experience ICU admission when diagnosed with COVID-19 compared with similar adults without excess weight.

The Curetis Unyvero Lower Respiratory Tract, or LRT, anel showed similar clinical sensitivity and specificity compared conventional cultures for specimens in patients with suspected pneumonia, according to a recent study.